

MANULIFE DANA EKUITAS TEKNOLOGI KESEHATAN GLOBAL DOLAR

MAR 2023

Investment Objective


To achieve long term capital growth by investing mainly in equity securities of companies which predominant economic activities are in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology sectors, onshore and/or offshore, directly and/or through mutual fund(s).

Fund Information

Inception Date	: 18 Oct 21
Inception Price	: USD 1.0000
Fund Size	: USD 3,944,894.74
Number of unit	: 4,008,217.17
Net Asset Value/Unit ⁽³⁾	: USD 0.9842
Fund Currency	: USD
Type of fund	: Equity
Valuation	: Daily
Custodian Bank	: Bank DBS Indonesia
Annual Management Fee	: 2.50%
Bloomberg Code	: MATKGMU IJ
Fund Manager	: PT Manulife Aset Manajemen Indonesia

Risk Classification

Risk classification is based on type of fund.



Allocation

Equity	: 80 - 100 %
Money Market	: 0 - 20 %


Portfolio

Equity	: 99.40%
Money Market	: 0.60%


Note

- 1) Annualized (1 year = 365 days) and using compound method (for products that have been more than one year old since inception).
- 2) The benchmark is MSCI World Health Care Index.
- 3) The Net Asset Value / Unit has calculated the costs, including fees related to transaction and transaction settlement as well as administration and recording.

Performance Since Inception



Monthly Performance Last 3 Years




Fund Performance

Performance in USD per (31/03/23)									Yearly Performance								
	1 mo	3 mo	6 mo	YTD	1 yr	3 yr ¹⁾	5 yr ¹⁾	Since Inception ¹⁾		2022	2021	2020	2019	2018	2017	2016	2015
MANTKG	3.24%	-2.11%	8.38%	-2.11%	-4.40%	n/a	n/a	-1.09%	MANTKG	-4.60%	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BM ²⁾	3.25%	-1.60%	11.33%	-1.60%	-3.69%	n/a	n/a	0.26%	BM ²⁾	-5.68%	n/a	n/a	n/a	n/a	n/a	n/a	n/a

Top Holdings* & Sector Allocation

Mutual Fund - BlackRock Global Funds - World Healthscience Fund



*Non Affiliates

Investment Manager Commentary

The healthcare equity market was weaker in the first half of March, but managed to rebound and posted positive return for the month. The collapse of several US banks and Credit Suisse in Europe raised concern of financial crisis like in 2008. However, quick reaction from the regulators managed to calm the markets and avoid wider contagion risks. Market sentiment also supported by expectation of The Fed nearing its peak rate hike cycle, signaled by The Fed's recent projection that terminal rate expected to be at 5.1%, one rate hike away from current level 5.0%. The fund continues to focus to invest on companies with attractive valuation, stable growth, and promising product pipelines. We see attractive innovation and technological developments in the biotechnology, pharmaceuticals, and medical devices space.

Disclaimer: This report is prepared by PT Asuransi Jiwa Manulife Indonesia only for information purposes and not to be used as a sales offering or proposal. Although this report has been prepared meticulously, PT Asuransi Jiwa Manulife Indonesia does not guarantee its accuracy, sufficiency or completeness, and is not responsible for any consequences arising from any actions which are based on the information stated herein. Investments in capital market instruments are subject to various risks which include, but not limited to, market risk, credit risk, interest rate risk, exchange rate risk (particularly in Fund which has allocation in offshore investment instruments in different currencies than the Fund's currency), liquidity risk and other risks which could result in performance volatility. Therefore, the performance of this Fund is not guaranteed, the unit price of each Fund may go up or down and past performance does not necessarily indicative of future performance.

Manulife Indonesia

Established in 1985, PT Asuransi Jiwa Manulife Indonesia (Manulife Indonesia) is part of Manulife Financial Corporation Group, a Canadian financial services group that operates in Asia, Canada and the United States. Manulife Indonesia offers a wide range of financial services, including life insurance, accident and health insurance, investment and pension plans to individual customers and group clients in Indonesia. Through a network of almost 11,000 employees and professional agents spread across more than 25 sales offices, Manulife Indonesia serves more than 2 million customers in Indonesia. PT Asuransi Jiwa Manulife Indonesia are licensed and supervised by the Otoritas Jasa Keuangan (OJK). To learn more about Manulife Indonesia, follow us on Facebook, Twitter, Instagram, YouTube, or visit www.manulife.co.id.